TY - JOUR T1 - Feasibility and safety of propofol sedation in flexible bronchoscopy JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p3710 AU - Peter Grendelmeier AU - Gabriel Kurer AU - Eric Pflimlin AU - Michael Tamm AU - Daiana Stolz Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p3710.abstract N2 - Background: Propofol is a sedative-hypnotic with a rapid onset of action. There are only limited data evaluating propofol for flexible bronchoscopy. We analyzed the feasibility and safety of propofol for bronchoscopy in a high output tertiary care center.Methods: Prospective data on patients undergoing flexible bronchoscopy at the University Hospital Basel, Switzerland were analyzed. Patient demographics, ASA class, Mallampati class, indication for bronchoscopy, bronchoscopic procedures, duration of examination, medication requirements, minor and major adverse events, hemodynamic parameters, as well as cough scores during the procedure were documented. Patients were followed up to discharge from the bronchoscopy suite.Results: Data on 440 patients with mean age 60 years (± 15.5, 260 male) were analyzed. Main indication for bronchoscopy was suspicion of malignancy. The most common diagnostic procedures were bronchoalveolar lavage in 253 cases (31.5%) and bronchial washing in 174 cases (21.7%). The mean duration of the procedure was 19.6 min (± 12.08). The mean propofol dose was 200 mg (± 107.5) corresponding to 2.89 mg/kg (± 1.70). Minor adverse events included oxygen desaturation in 72 (16.4%), hypotension in 68 (15.4%) and minor bleeding in 11 (2.5%) patients. No major adverse events were recorded. The median decline in systolic blood pressure after initiation of sedation was 14 mmHg (3 - 28). A drop in systolic blood pressure greater than 20 mmHg was observed in 166 of the 440 patients (37%).Conclusion: Propofol sedation for flexible bronchoscopy is feasible and safe. ER -